Skip to main content

Biogen balance sheet

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

At the end of fiscal 2025 (the year to 31 Dec 2025), Biogen reported total assets of $29.44B, $3.01B in cash and equivalents, $6.66B of total debt; shareholders' equity was $18.26B.

From Biogen's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Biogen balance sheet, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$659.7M$622.4M$581.9M$759.6M$514.5M$570.7M$602.6M$1.20B$1.31B$2.33B$1.57B$1.22B$2.91B$1.33B$2.26B$3.42B$1.05B$2.38B$3.01B
Short-term investments—$719.6M$681.8M$448.1M$1.18B$1.13B$620.2M$640.5M$2.12B$2.57B$2.12B$2.31B$1.56B$1.28B$1.54B$1.47B$0.00$0.00$807.2M
Cash and short-term investments$659.7M$1.34B$1.26B$1.21B$1.69B$1.71B$1.22B$1.85B$3.43B$4.90B$3.69B$3.54B$4.48B$2.61B$3.80B$4.89B$1.05B$2.38B$3.82B
Accounts receivable—$446.7M$551.2M$605.3M$584.6M$686.8M$824.4M$1.29B$1.23B$1.44B$1.79B$1.96B$1.88B$1.91B$1.55B$1.71B$1.66B$1.40B$1.34B
Inventory—$263.6M$293.9M$289.1M$326.8M$447.4M$659.0M$804.0M$893.4M$1.00B$902.7M$929.9M$804.2M$1.07B$1.35B$1.34B$2.53B$2.46B$2.17B
Current assets—$2.46B$2.48B$2.54B$2.98B$3.24B$3.18B$4.54B$6.70B$8.73B$7.87B$7.64B$8.38B$6.89B$7.86B$9.79B$6.86B$7.46B$8.97B
Property, plant and equipment—$1.59B$1.64B$1.64B$1.57B$1.74B$1.75B$1.77B$2.19B$2.50B$3.18B$3.60B$3.25B$3.41B$3.42B$3.30B$3.31B$3.18B$3.06B
Goodwill—$1.14B$1.14B$1.15B$1.15B$1.20B$1.23B$1.76B$2.66B$3.67B$4.63B$5.71B$5.76B$5.76B$5.76B$5.75B$6.22B$6.48B$6.49B
Acquired intangibles—$2.16B$1.87B$1.77B$1.61B$1.63B$4.47B$4.03B$4.09B$3.81B$3.88B$3.12B$3.53B$3.08B$2.22B$1.85B$8.36B$9.69B$9.18B
Long-term investments—$891.4M$1.19B$743.1M$1.42B$2.04B—————————————
Total assets—$8.48B$8.55B$8.09B$9.05B$10.13B$11.86B$14.31B$19.50B$22.88B$23.65B$25.29B$27.23B$24.62B$23.88B$24.55B$26.84B$28.05B$29.44B
Accounts payable—$107.4M$118.5M$162.5M$186.4M$204.0M$219.9M$229.2M$267.4M$279.8M$395.5M$370.5M$530.8M$454.9M$589.2M$491.5M$403.3M$424.2M$432.0M
Unearned revenue, current——$38.70M$41.30M$69.60M$148.0M$172.7M$120.9M$55.70M——————————
Long-term debt · current portion—$27.67M$19.76M$137.2M$3.29M$453.4M$3.49M$0.00$1.70M$1.70M$0.00$0.00$1.50B$0.00$999.1M$0.00$150.0M$1.75B$0.00
Current liabilities—$923.2M$714.9M$1.05B$912.9M$1.66B$1.76B$2.22B$2.58B$3.42B$3.37B$3.30B$4.86B$3.74B$4.30B$3.27B$3.43B$5.53B$3.35B
Long-term debt · non-current———————$0.00$18.10M$16.40M$0.00————————
Operating lease liability————————————$486.3M$485.2M$419.5M$430.2M$490.3M$420.9M$370.8M
Total liabilities—$2.65B$2.29B$2.64B$2.62B$3.17B$3.24B$3.50B$10.13B$10.75B$11.05B$12.26B$13.90B$13.93B$12.92B$11.17B$12.05B$11.33B$11.18B
Retained earnings—$270.2M$1.07B$1.87B$3.11B$4.49B$6.35B$9.28B$12.21B$15.07B$15.81B$16.26B$16.46B$13.98B$13.91B$16.47B$17.63B$19.26B$20.55B
Minority interest—$27.87M$40.35M$52.94M$1.49M$2.27M$596.0K$5.00M$2.10M−$11.50M−$14.70M−$8.00M−$4.10M−$14.20M$63.50M−$9.50M$0.00——
Shareholders' equity$5.55B$5.81B$6.22B$5.40B$6.43B$6.96B$8.62B$10.81B$9.37B$12.14B$12.61B$13.04B$13.34B$10.70B$10.90B$13.40B$14.80B$16.72B$18.26B
Total liabilities and equity—$8.48B$8.55B$8.09B$9.05B$10.13B$11.86B$14.31B$19.50B$22.88B$23.65B$25.29B$27.23B$24.62B$23.88B$24.55B$26.84B$28.05B$29.44B
Total debt———$1.04B$1.02B$687.4M$592.4M$0.00$19.80M$6.52B$5.94B$5.94B$4.95B$7.91B$6.69B$6.71B$7.28B$4.97B$6.66B
Net debt———−$172.5M−$667.0M−$1.02B−$630.3M−$1.85B−$3.41B$1.62B$2.25B$2.40B$469.4M$5.30B$2.89B$1.82B$6.23B$2.59B$2.84B
Net working capital—$912.4M$1.18B$730.7M$1.55B$1.02B$824.1M$1.11B$2.81B$2.99B$2.93B$3.12B$604.3M$1.81B$1.30B$3.10B$2.38B−$447.0M$2.62B
Shares outstanding · period end—288M275M241M242M237M236M235M219M216M212M197M174M152M147M144M145M146M147M

Quarterly

Biogen balance sheet, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Cash and equivalents$1.05B$1.07B$1.91B$1.70B$2.38B$2.60B$2.76B$3.86B$3.01B$3.38B$1.28B$1.30B
Short-term investments$0.00———$0.00——$97.60M$807.2M$900.0M$0.00$0.00
Cash and short-term investments$1.05B$1.07B$1.91B$1.70B$2.38B$2.60B$2.76B$3.96B$3.82B$4.28B$1.28B$1.30B
Accounts receivable$1.66B———$1.40B———$1.34B———
Inventory$2.53B$2.52B$2.51B$2.47B$2.46B$2.27B$2.27B$2.21B$2.17B$1.95B$2.38B$2.22B
Current assets$6.86B$6.76B$7.11B$6.83B$7.46B$7.63B$7.97B$8.94B$8.97B$9.19B$7.31B$7.58B
Property, plant and equipment$3.31B$3.28B$3.25B$3.21B$3.18B$3.13B$3.10B$3.08B$3.06B$3.02B$2.99B$2.97B
Goodwill$6.22B$6.23B$6.23B$6.49B$6.48B$6.48B$6.49B$6.49B$6.49B$6.49B$6.99B$6.99B
Acquired intangibles$8.36B$8.28B$8.23B$9.81B$9.69B$9.58B$9.47B$9.33B$9.18B$9.05B$13.52B$13.38B
Total assets$26.84B$26.57B$26.80B$28.31B$28.05B$28.03B$28.33B$29.21B$29.44B$29.48B$32.09B$32.05B
Accounts payable$403.3M$387.0M$354.5M$422.7M$424.2M$391.5M$408.4M$413.1M$432.0M$358.5M$403.9M$430.3M
Long-term debt · current portion$150.0M$250.0M$0.00$1.75B$1.75B$1.75B$0.00$0.00$0.00———
Current liabilities$3.43B$3.22B$3.11B$5.42B$5.53B$5.30B$3.18B$3.29B$3.35B$3.00B$3.92B$3.90B
Operating lease liability$490.3M———$420.9M———$370.8M———
Total liabilities$12.05B$11.35B$10.91B$11.95B$11.33B$11.05B$10.70B$11.00B$11.18B$10.83B$13.24B$13.13B
Retained earnings$17.63B$18.02B$18.60B$18.99B$19.26B$19.50B$20.14B$20.60B$20.55B$20.87B$20.97B$20.95B
Minority interest$0.00———————————
Shareholders' equity$14.80B$15.21B$15.89B$16.36B$16.72B$16.98B$17.63B$18.21B$18.26B$18.65B$18.85B$18.92B
Total liabilities and equity$26.84B$26.57B$26.80B$28.31B$28.05B$28.03B$28.33B$29.21B$29.44B$29.48B$32.09B$32.05B
Total debt$7.28B$6.70B$6.66B$4.90B$4.97B$4.87B$6.59B$6.59B$6.66B$6.56B$7.56B$7.40B
Net debt$6.23B$5.62B$4.75B$3.20B$2.59B$2.27B$3.84B$2.63B$2.84B$2.28B$6.27B$6.10B
Net working capital$2.38B$2.46B$2.09B−$293.7M−$447.0M−$269.7M$2.03B$1.78B$2.62B$2.81B$2.10B$2.38B
Shares outstanding · period end145M146M146M146M146M147M147M147M147M148M148M148M

The main figures as JSON and plain text. See data and methodology.

BIIB in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.